Last Updated on December 31, 2023 by The Health Master
AstraZeneca Pharma India has received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India (DCGI) for Osimertinib 40mg/80mg film-coated tablets (Tagrisso).
Osimertinib 40mg/80mg film-coated tablets as monotherapy is now approved for additional indication for the adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon19 deletions or exon 21 (L858R) substitution mutations.
The receipt of this permission paves way for the launch of Osimertinib 40mg/80 mg film-coated tablets into a new disease area in India, subject to the receipt of related statutory approvals and licenses.
Also read:
Lupin launches generic Nitazoxanide tablets
Dr Reddy’s gets 3 observations from USFDA for US-based API plant
World’s most expensive drug, costs ₹18 crore per dose
NATCO gets USFDA nod for Breast Cancer treatment drug
Kite gets USFDA nod for drug to treat Follicular Lymphoma
Shilpa Medicare gets USFDA tentative nod for drug for Arthritis
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
